Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Citalopram: a comprehensive review.

B G Pollock1

  • 1University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213-2593, USA. PollockBG@msx.upmc.edu

Expert Opinion on Pharmacotherapy
|May 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of dorsolateral prefrontal cortex structural measures on neuroplasticity and response to paired-associative stimulation in Alzheimer's dementia.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2024
Same author

Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease.

Molecular psychiatry·2016
Same author

Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.

Pharmacopsychiatry·2015
Same author

In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA.

Molecular psychiatry·2015
Same author

The SORL1 gene and convergent neural risk for Alzheimer's disease across the human lifespan.

Molecular psychiatry·2013
Same author

Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

Molecular psychiatry·2011
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Citalopram, a selective serotonin re-uptake inhibitor, effectively treats depression and related conditions. This review covers its broad clinical efficacy, safety, and tolerability across diverse patient groups.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Selective serotonin re-uptake inhibitors (SSRIs) are a key class of antidepressants.
  • Serotonergic dysfunction is implicated in various psychiatric and neurological disorders.
  • Citalopram is an established SSRI with a known mechanism of action.

Purpose of the Study:

  • To review the comprehensive clinical efficacy of citalopram.
  • To evaluate the safety and tolerability profile of citalopram.
  • To explore citalopram's utility in a wide range of patient conditions.

Main Methods:

  • Systematic review of controlled clinical trials.
  • Analysis of studies investigating citalopram in various disorders.
  • Assessment of safety and tolerability data from clinical use.

Related Experiment Videos

Main Results:

  • Citalopram demonstrates significant antidepressant efficacy.
  • The drug shows benefits in anxiety, panic disorder, OCD, and dementia-related behavioral issues.
  • Evidence supports its use in alcohol dependence and premenstrual dysphoria.

Conclusions:

  • Citalopram is a versatile medication with established efficacy beyond depression.
  • Its safety and tolerability are well-documented across multiple indications.
  • The review confirms citalopram's broad clinical utility in serotonergic dysfunction-related conditions.